RO135640A0 - Use of immunoglobulins y for skin and mucosal diseases - Google Patents

Abstract

The invention relates to a biologically active product composition with antibacterial, antifungal and virucidal action based on specific antibodies in combination with healing, re-epithelializing and restructuring substances to be used in skin and mucosal diseases. According to the invention, the composition consists in mass percentages of 10 ... 70% polyclonal or monoclonal antibodies IgY, 3 ... 5% honey, 2..3% nicotinamide, 0.5 ... 1% Arnica Montana, Calendula Officinalis and Aloe extracts, respectively, and for the remainder pharmaceutically acceptable ingredients for the formulation as a solution, gel, cream or ovules.

Description

STATE ORQU FOR BROWN COATINGS Application for Invention Patent _No <x 0£.:$.%иб..........

APPLICATION FOR PATENT OF INVENTION

TITLE:

THE USE OF IMMUNOGLOBUNES Y IN DISEASES OF THE SKIN and MUCOSA (Innovative biologically active products, containing specific antibacterial and antiviral Y Antibodies, in combination with cicatrizing, re-epithelializing, restructuring substances, for dermatological use.)

ABSTRACT

The present patent represents the invention related to the creation of a range of biologically active products having as the main active component Immunoglobulins Y (mono-specific or poly-specific), for cutaneous, oral and parenteral use.

For the first time worldwide, Immunoglobulins Y are associated with other biologically active substances, for the synergistic potentiation of their cumulative effects, namely with CBD oil intended for products for dermal use, and with the bacterium Faecalibacterium prausnitzii, for the treatment of chronic inflammatory conditions of the intestine.

The qualities of avian Y immunoglobulins, in combating various infectious diseases, local or general, no longer need to be demonstrated, they are known and recognized worldwide, and proven by hundreds of clinical studies. The principle of passive immunization has been used for over 100 years, and sera containing antibodies are widely used throughout the world (anti-rabies serum, anti-tetanus serum, anti-diphtheria serum, etc.). Most of these sera carrying specific antibodies are produced by immunizing some species of mammals, and the purification process for human administration is difficult and long, due to FC activation and the risk of anaphylactic reactions.

The opportunity to use Immunoglobulins Y consists in obtaining biologically active products whose main characteristic is that they do NOT activate the complement factor, which is why anaphylactic risks are non-existent, and local or oral administration is free of short, medium or long-term side effects.

The phenomenon of resistance to antibiotics or antivirals of many microorganisms, bacteria or viruses, represents a problem of worldwide interest, considered by the WHO to be an extreme danger for the loss of human lives in the coming decades.

The application of IgY Technology in the field of human health is functional, practical, efficient, without negative consequences on the human body, and respects all the ethical principles of the profession.

DESCRIPTION

The use of IgY antibodies for human use has been a globally accepted practice since 1996, and the Swiss government's Veterinary Office (Office Veterinaire Federal) approved the practice in 1999.

IgY technology has been applied since the 1990s, describing various methods of immunizing birds, obtaining Y immunoglobulins, polyclonal or monodonal, and using them on a large scale in the field of biotechnology and biomedicine.

Countries with a known scientific and research activity, such as the USA, Japan, Canada, etc. studied and applied in practice the various types of Immunoglobulin Y, obtaining exceptional results. Hundreds of clinical studies have proven its benefits, and a series of products from the range of food supplements or dermato-cosmetic products are already authorized, manufactured and distributed in these countries.

The emergence of antibiotic and antiviral resistance among infection-causing organisms represents a critical challenge for the global health care community. New approaches to treating and managing infections are urgently needed.

Passive immunization represents an extremely attractive potential alternative to meet this need. Immunoglobulin Y (IgY) antibodies have previously been used against bacterial and viral infections in humans and animals, but without progressing to the stages of designing effective, scientifically supported products. The advantages of these immunoglobulins include lack of reaction with mammalian Fc receptors, low production cost and ease of extraction. Compared to mammalian IgGs, they have higher target specificity and higher binding avidity. It also has a remarkable activity of neutralizing pathogens from the respiratory tract, the digestive system, the excretory system, and, in general, from most of the body's structures. (1, 36,17,27)

Due to their protein structure, preparations containing IgY antibodies were initially considered to be unstable and partially destroyed by digestion. However, numerous studies have proven the effectiveness of orally administered IgY against infectious agents, the antibodies being stable at acidic pH, above pH 3, as well as at alkaline pH, up to pH 11. The binding capacity of IgY to the target antigens resists stable up to 60-70 degrees. IgY remains stable for 5 years at temperatures of 4 degrees Celsius, and 30 days at 37 degrees Celsius, without loss of activity.

demand

1. Methods of treatment and administration of biologically active products containing Immunoglobulin Y in skin conditions.

1.1. The group of dermatological conditions of the lower limbs, including infected wounds, varicose ulcers and ischemic ulcers, bedsores, diabetic foot wounds. The treatment method involves the use of the following products and procedures:

a. Skin disinfection using 0.02% hypochlorous acid solution.

b. Applying a jet of solution containing polydonal IgY antibodies to open, infected wounds.

c. Application of a gel layer containing polydonal or monoclonal IgY antibodies (depending on the bacteriological examination), moisturizing, restructuring, anti-inflammatory compounds, with or without the collagen membrane, under an absorbent dressing, changed every 24 hours.

d. Changing the dressing daily, repeating the procedure from points a-c, until the regeneration buds appear and a sterile result is obtained in the bacteriological examination.

e. Application of a layer of cream containing IgY antibodies, restructuring, calming, cicatrizing components, until the wound is completely epithelialized, under an occlusive dressing, changed at most 48 hours.

Product components and recipes:

A. ANTIBACTERIAL, ANTIFUNGAL, VIRUCIDAL SOLUTION, contains hypochlorous acid 0.0180.02%, 150ml bottle with sprayer

B. POLYCLONAL IgY ANTIBODIES SOLUTION (DERMYMUN)

Formula

yl

- IgY polyclonal antibodies 10-30% - Silver AG-P Water 5-10% - Honey (White) Extract 1-5% - Nikkosome 3-5% - Nicotinamide 2-4% - Hydrolyzed Hyaluronic Acid 0.05-0.1% - Purified water qs.ad 100

C. ANTIBACTERIAL, REPAIRING GEL (DERMYMUN GEL)

- Polyclonal or monoclonal IgY antibodies depending on the bacteriological profile of the patient 10-70% - Honey (White) Extract 1-5% - Nikkosome penetration vector 2-5% - Nicotinamide 2-4% - Genencare OSMS BA betaine from beet 1-2% - Glycerin 2-3% - Integrin 60 (oligopeptides) 1-2% - Mimosa Tenuiflora Bark Extract 1-2% - Xanthan Gum 0.5-1% - Hydrolyzed collagen 0.5-1% - Sacrum (Aphanoteche Sacrum) 0.5-1% - Amica Montana Flower Extract 0.5-1% - Hydrolyzed Hyaluronic Acid oligo 0.05-0.1%

u

- Nipagin (Para hydroxy methyl benzoate) or other preservative 0.1-0.15% - Purified water qs.ad 100

D. COLLAGEN MEMBRANE IMPREGNATED WITH HYALURONIC ACID, OR VITAMIN C OR DETOXIFYING MEMBRANE WITH CHARCOAL, depending on the type of skin damage.

F. RESTRUCTURING, CICATRIZING CREAM (DERMYMUN)

- Polydonal or monoclonal antibodies depending on the bacteriological profile of the patient 10-40% - Squalane 5-10% - Caprylic Capric Triglycerides 3-5% - Emulium Delta GATEFOSSE (Cetearyl Alcohol, Glyceryl Stearate) 3-5% - Sodium PCA 2-4% - Anesthesia 1-2% - Glyceryl stearate 1-2% - PEG-8 Beeswax 1-2% - Betaine from beets 1-2% - Essential amino acids 1-2% - lntegrin-60 oligopeptides from rice 1-2% - Euxyl PE 9010 0.5-0.8% - Hippophae Rhamnoides Oii 0.5-1% - Cannabidiol 0.5-1% - Amica Montana flower extract 0.5-1%

- Calendula Officinalis Extract 0.5-1% - Q-enzyme Q10 0.2-0.3% - Caprylyl glycol 0.2-0.3% - Xanthan gum 0.2-0.3% - Allantoin 0.1-0.2% - Hydrolyzed hyaluronic acid 0.1-0.2% - Disodium EDTA 0.1-0.2% - Purified water qs ad qs.ad. 100

1.2. Acne Dermatology Group.

The treatment method involves the use of the following products and procedures:

a. Skin disinfection using 0.02% hypodorus acid solution.

b. Application of a jet of solution containing IgY anti Staphylococcus and anti Propionae bacterium acne antibodies.

c. Application of a gel containing anti-Staphylococcus and anti-Propionae bacterium acne IgY antibodies, together with moisturizing, soothing, sebum-absorbing, scar-free products, until the acne elements and signs of local inflammation disappear.

d. Application of a professional anti-acne cream, containing IgY antibodies against Staphylococcus and anti Propionae bacteria, together with natural components: plant extract and specific oils, the cream used daily.

Product components and recipes:

a. DISINFECTANT, ANTIBACTERIAL, VIRUCIDAL SOLUTION, with hypochlorous acid 0.0180.02% 100-150 ml bottle (DERMYMUN).

G. ANTI-ACNEIC TONER (DERMYMUN)

- Ag-P-Water 5-10% - Azeloyl Glycine (Potassium azeloyl diglycinate) 3-5% - Butylene glycol 3-5% - Honey (White) Extract 3-5% - Glycerin 2-3% - Salixin (Salix Purpurea extract) 1-2% - Mimosa Tenuiflora bark extract 1-2% - Epilobium Angustifolium Bark extract 1-2% - Retinaturel 05 0.5-1% - Hydrolyzed Milk Protein 0.5-1% - Euxyl PE 9010 0.5-0.8% - Caprylyl Glycol 0.2-0.3% - Allantoin 0.1-0.2% - Purified water qs.ad 100

H. ANTI-ACNE GEL- OIL FREE (DERMYMUN)- 50 ml airless bottle

- IgY antibodies against staphylococcus and against Propionum bacterium 10-50% - Honey (White) extract 3-5% - Genencare OSMS BA 1-2% - Matmarine (Pseudoalteromonas Ferment Extract) 3-5% - Iris Florentina extract, zinc sulfate, retinyl palmitate) 2-4% - Salixin (Salix Purpurea) Extract 1-2%

- Calendula Oficinalisflower extract 1-2% - RETINATUREL 05 0.5-1% - Ammonium Acryloyl Dimetyl Taurate/VP Copolymer 0.3-0.5% - Euxyl PE 9010 0.6-0.8% - Simulgel EG (Sodium Acrylate/Sodium Acryloyl di methyl Taurate Copolymer/lsoxhexadecane/Polysorbate 80 1-3% - Allantoin 0.1-0.2% - Caprylyl Glycol 0.2-0.3% - Purified water q.s ad 100

I. PROFESSIONAL YEARS AND ACNE CREAM airless bottle 50 ml (DERMYMUN)

- IgY antibodies against staphylococcus and against PropionaebacteriumAcne 10-20% - Sour azalea 5-10% - Butylene glycol 10-15% - Emulsun (Hydrogenated Sunflower Seed Oii Polyglyceryl-3Esters (and) Hydrogenated Sunflower Seed Oii Glyceryl Esters and Cetearyl Alcohol and Sodium Stearoyl Lactylate 3-4% - Hemisqualane 3-4% - Glycerin 2-3% Saboflow VL (Sodium Polyacrylate, Hydrogenated Polydecene Trideceth-6) 2-3% - Epilobium Angustifolium Bark Extract (Willowherb) 1-2% - Mimosa Tenuiflora Bark Extract 1-2%

- Sepimax Zen (Polyacrylate Crosspolymer-6) 1-2% - Orgasol (Nylon 12) 1-2% - Normaseb ph (Hydrolyzed milk protein) 0.5-1% - Sebopessine (Polyisoprene, Glycine Soya Sterols) 0.5-1% - Aloe Barbadensis Leaf Extract 0.5-1% - Calendula Officinalis Flower extract 0.5-1% - Cannabidiol 0.5-1% - Euxyl PE 9010 0.5-0.8% - Alpha Bisabolol 0.2-0.3% - Caprylyl Glycol 0.2-0.3% - Allantoin 0.1-0.2% - Glycyrrhetinic Acid 0.1-0.2% - Manuka Oii (Leptospermum Scoparium Branch Leaf Oii 0.1-0.2% - Mentha Arvensis Oii 0.05-0.1% - Purified water qs ad 100

1.3. Group of products for psoriasis.

The treatment method involves the use of the following products and procedures:

a. Skin disinfection using a 0.02% solution of hypochlorous acid.

b. Application of a jet of solution containing polyclonal IgY antibodies.

c. Gel containing antibacterial and antiviral antibodies, together with Sacran, Liftonil, plant extracts, Iris florentina, APHANOTECHE SACRUM algae extracts, etc.,

administered daily, until the disappearance of the superficial elements characteristic of psoriasis.

d. Maintenance cream with polyclonal IgY antibodies, Salixin, nicotinamide, etc., applied daily.

a. DERMYMUN DISINFECTANT, ANTIBACTERIAL, VIRUSOCIDAL SOLUTION - contains hypochlorous acid 0.018-0.02 150ml bottle with sprayer

J. PSORYMUN - POLYCLLONAL IgY ANTIBODIES SOLUTION

150 ml spray bottle containing: -IgY polyclonal antibodies 20-40% -Nikosome PV- 3-5% -AG-P 5-10% -Nicotnamide 3-4% -Sodium Ascorbyl Phosphate 0.5-1% -Hydrolyzed Hyaluronic Acid 0.05-0.1% - Nipagin 0.1%-0.2% -Salixin (Salix Purpurea) 1-2% -Purified water qs. ad 100

K. PSORYMUN MOISTURIZING REPAIR GEL

- Antibacterial and antiviral antibodies 10-30% - Sodium PCA 3-5% -Honey (White) Extract 3-5% - Genencare OSMS BA betaine from beet 1-2% - Simulgel EG 1-3%

- Salixin (Salix Purpurea) 1-2% - White Betula Leaf Extract 1-2% - SacranBG (Aphanoteche Sacrum) 1-2% - Aloe Vera Gel 1-2% - Retinaturel 05 0.5-1% - Cannabidiol CBD 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.60.8% - Chelidonium Majus Extract 0.5-1% - Ammonium Acryloyl Dimethyl Taurate (Flocare) 0.3-0.5% - Caprylyl Glycol 0.2-0.3% - Juniperus Oxycedrus Wood Extract 0.1-0.2% - Melaleuca Alternifolia Oii Leaf (Tea Tree) 0.05-0.1% - Hydrolyzed Hyaluronic Acid oligo 0.05-0.1% - Purified water q.s ad.100

L PSORYMUN PLANT NATURAL DERMOACTIVE CREAM

- Antibacterial and antiviral antibodies 5-30% -Glycerin 2-3% - Xanthan Gum 0.2-0.35% - Emulactive W (Cetearyl Alcohol, Glyceryl Stearate (and) Potassium Palmitoyl Hydrolized Wheat Protein 8-10% - Plantasens LD 10-20%

-Sweet Almond Oii 5-10% -Rice Sativa (Rice) Sheep brain 5-10% -Abyssinian Oii Brassica Nigra Oii 3-5% - Squalane 3-5% -Cannabidiol 2-3% - Shea Butter (Butyrospermum Parkii) 2-5% -Nicotinamide 2-3% - Salixin (Purple Sage) Extract 1-2% - White Birch Leaf Extract 0.5-1% -Retinaturel 05 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% -Coenzyme Q10 0.05-0.1% -Tocopherol 0.2-0.3% - Caprylyl Glycol 0.2-0.3% -Hydrolyzed Hyaluronic Acid 0.05-0.1% -Melaleuca Alternifolia Sheep Leaf 0.05-0.1% - Purified water qs ad 100

If the psoriatic rash is present on large body surfaces or on the hands, wrapping in plastic film at night after applying the cream is indicated. It is also recommended to apply absorbent dressing to the affected areas during the night, which allows hydration, exfoliation and healing of the epidermis. Oral administration of products with a role in immunomodulation of the immune response is also indicated for patients with psoriasis.

^2-

1.4. The group of products for burns.

The treatment method involves the use of the following products and procedures:

a. Skin disinfection using a 0.02% solution of hypochlorous acid.

b. Spraying on the areas affected by burns, a solution containing IgY polyclonal antibodies, together with ovomucin, ovotransferrin, lysozyme, and silver water.

c. Gel containing IgY polyclonal antibodies, specific extracts and the collagen membrane, applied daily, with or without an odusive dressing, until the burn wounds are epithelized.

d. Cream containing IgY polyclonal antibodies, along with restructuring, cicatrizing, re-epithelializing components, administered daily until healing.

a. DERMYMUN ANTIBACTERIAL, VIRUSOCID DISINFECTANT SOLUTION contains hypochlorous acid with a concentration of 0.018-0.02% 150 ml bottle with sprayer

M. POUCLONAL IgY ANTIBODIES SOLUTION, together with OVOMUCIN, OVOTRANSFERIN, LYZOZYME (DERMYMUN), 150 ml spray bottle

-IgY+ polyclonal antibodies Ovomucin, Ovotransferrin, Lysozyme 20-30% -AG-P -WATER 5-10% - Honey (White) Extract 3-5% -Hydrolyzed collagen 0.5-1% -Nicotinamide 2-3% -Sodium Ascorbyl Phosphate 0.5-1% -Hydrolyzed hyaluronic acid 0.05-0.1% -Nipagin (Para Hydroxy Methyl Benzoate) 0.1-0.2% - Purified water qs.ad 100

N. Antibacterial, restructuring, scarring gel (DERMYMUN)

Polyclonal antibodies Igy- Ovomucin, Ovotransferrin, Lysozyme 10-30% - AG-P Water 5-10% - Honey (White) Extract 3-5% - Nikkosome 3-5% - Sacrum (Aphanoteche Sacrum) 1-2% - Hydrolyzed collagen 0.5-1% -Integrin 60 (Rice proteins-oligopeptides) 1-2% - Simulgel EG 1-3% -Aloe vera gel 1-2% -Cannabidiol 0.5-1% -Flocating gelling agent 0.3-0.5% - Allantoin 0.1-0.2% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.5-0.8% - Caprylyl Glycol 0.2-0.3% - Purified water qs ad 100

O. DERMYMUN HYDRATING, CALMING, RESTRUCTURING CREAM

Airless bottle 50 ml

-IgY+ polyclonal antibodies Ovomucin, Ovotransferrin, Lysozyme 10-30% -Glycerin 1-3% - Xanthan Gum 0.2-0.35% -Emulactive W —-------- 8-10%

- Plantasens LD 10-20% -Sweet Almond 5-10% -Rice Sativa (Rice) Brain Oii 5-10% -Abyssinian Sheep Brassica Nigra 3-5% - Squalane 3-5% - Anesthesia 2-3% - Cannabidiol 1-2% - Butyrospermum Parkii 2-5% - Nicotinamide 2-3% - Integrin 60 (proteins from rice hydrolyzed oligopeptides 1-2% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% - Natural tocopherol 0.2-0.3% - Alpha Bisabolol 0.2-0.3% - Coenzyme Q.10 0.1-0.2% - Allantoin 0.1-0.2% - Hydrolyzed Hyaluronic Acid Oligo 0.05-0.1% - Melaleuca Alternifolia (Tea Tree Oii) 0.05-0.1% - Purified water qs.ad 100

The most adapted therapeutic approach is the use of a collagen membrane, over which the solution from point M is generously sprayed, for the first applications. Later, over the same collagen membrane, the moisturizing gel is applied and bandaged for 24 days

1.5. The group of products for the female genital sphere.

- Antibacterial disinfectant solution against bacteria specific to the area (Candida Albicans, Escherichia Coli, Papilloma Virus, Enterococcus, etc.) Washes are done daily by spraying this disinfectant solution, followed by the application of the restorative soothing gel or cream

a. DISINFECTANT, ANTIBACTERIAL, VIRUSOCIDAL SOLUTION contains hypochlorous acid 0.018-0.02 in a 150 ml bottle with sprayer. Local washes are done with this solution daily.

P. MOISTURIZING GEL, ANTIBACTERIAL, INTIMATE HYGIENE DERMYMUN), contains:

- Area-specific IgY antibodies mentioned above 20-50% -AG-P-Water silver water 3-5% - Honey (White) Extract 3-5% - Sacran (Aphanoteche Sacrum) 0.5-1% -Essential amino acids 1-2% -Genencare OSMS BA betaine from beets 1-2% -Glycerin 2-3% - Malva Sylvestris or Althea Officinalis Extract 1-2% -Aloe Vera Gel 1-2% -Octyl Palmitate 3-4% -Sepigel 305 (Polyacrylamide C13- 14lsoparaffin/Laureth 7) 2-4% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% - Caprylyl Glycol 0.2-0.3%

- Allantoin 0.1-0.2% -Hydrolyzed Hyaluronic Acid 0.05-0.1% - Purified water qs.ad 100

Q. MOISTURIZING, SOOTHING, RESTRUCTURING CREAM (DERMYMUN) contains:

-IgY antibodies specific to the genital area 10-40% - Squalane 5-10% -Caprylic Capric Triglycerides 3-5% - Emulium Delta 3-5% -Sodium PCA 2-5% -PEG 8 Beeswax 1-2% - General OSMS BA 1-2% -Essential amino acids 1-2% - Althea Officinalis or Malva Sylvestris 1-2% -Calendula Officinalis Extract 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% -Cannabidiol 0.5-1% -Coenzyme Q10 0.2-0.3% - Caprylyl glycol 0.2-0.3% - Xanthan Gum 0.2-0.35% - Allantoin 0.1-0.2% - Disodium EDTA 0.1-0.2% -Hydrolyzed Hyaluronic Acid 0.05-0.1%

- Purified water qs.ad 100

d. Vaginal ovules containing igY anti Papilloma Virus antibodies

A vaginal egg weighs 1.6 g, and contains:

Immunoglobulin Y against HPV 80 mg Colloidal silicon dioxide 20 mg Recutita Chamomills extract 60 mg Vitamin E acetate 10 mg Sodium hyaluronate 5 mg Glycerides (saturated fatty acids) 1425 mg

General bibliography

Clinical results obtained after 12 weeks of local treatment.

CLINICAL CASE 2.

Patient V.S., 67 years old, multiple comorbidities, hospitalized for left thigh phlegmon, septic condition. During hospitalization, the phlegmon is incised, and Klebsiella Pneumonia® MR and Pseudomonas Aeruginosa MR are bacteriologically isolated. In the case of both multiresistant bacteria, despite the antibiotic treatment, only a slight improvement of the general condition is obtained.

Local treatment with gel and cream containing specific anti-Klebsielia and anti-Pseudomonas A. _f immunoglobulins and oral administration of specific immunoglobulins against the same bacterial strains is initiated.

At the start of treatment:

After a period of 7 days from the initiation of treatment:

After 16 zH® from the start of treatment. BaderiolQtic examination negative. Good general condition, afebrile, no other charges.

CLINICAL CASE 3:

Patient B.R., 67 years old, female, chronic venous insufficiency, extensive varicose ulcer, infected, left calf. staphylococcal infection of the foot of the right foot. It is isolated from the wound: Proteus Mirabilis, Staphylococcus Âureus, Pseudomonas Aeruginosa, the last 2 bacteria being Multi-Resistant to antibiotics. Wounds older than 1§ months.

At the time of taking over the patient:

Local and general treatment begins with products containing specific immunoglobulins for Proteus Mirabilis, Staphylococcus Aureus, Pseudomonas Aeruginosa.

Healing of staphylococcal infection in the right foot after 33 days of treatment.

Varicose ulcer of the left leg without bacterial infections, in the process of epithelization.

CASE 4:

Patient S.N., 77 years old, diabetic, hypertensive. Amputation of the toes of the left foot, stump infected with Staphylococcus Aureus and Pseudomonas Aeruginosa, re-amputation proposal, refused by the patient.

Local and general treatment begins with products containing specific immunoglobulins against Staphylococcus Aureus and Pseudomonas Aeruginosa.

Evolution after 1 month and 3 months.

At present:

Clean wound, sterile bacteriological examination, over 90% re-epithelialized, in the process of complete healing.

CLINICAL CASE 5:

Patient M.L., 63 years old, female, infected abdominal wound after abdominoplasty, bacteriologically identified Proteus Mirabiiis.

At the time of presentation:

in evolution, under local treatment as gel + cream with specific Y Immunoglobules:

Currently, the wound is healed.

Patient S.N., 87 years old, male, chronic venous insufficiency with bilateral infected calf wounds.

The presence of worms in both wounds, massive edema, marked functional impotence of both lower limbs was noted.

Local treatment with gel and cream containing IgY is instituted.

Claims (15)

of 2021 00730/09.12.2021 demand Claims submitted according to art. tq aiin. 7 of law no. 64 /1991 on 1 8 ~0î~ 2022 1. Biologically active product in the form of an antibacterial, antifungal and virucidal solution, characterized by the fact that it consists in mass percentages of - IgY polyclonal antibodies 10-30% - Silver AG-P Water 5-10% - Honey (White) Extract 1-5% - Nikkosome 3-5% - Nicotinamide 2-4% - Hydrolyzed Hyaluronic Acid 0.05-0.1% - Purified water qs.ad 100 2. Biologically active product in the form of an antibacterial gel, characterized by the fact that it is constituted in mass percentages of Polyclonal or monoclonal IgY antibodies 10-70% - Honey (White) Extract 1-5% - Nikkosome penetration vector 2-5% - Nicotinamide 2-4% - Genencare OSMS BA betaine from beet 1-2% - Glycerin 2-3% - Integrin 60 (oligopeptides) 1-2% - Mimosa Tenuiflora Bark Extract 1-2% - Xanthan Gum 0.5-1% - Hydrolyzed collagen 0.5-1% - Sacrum (Aphanoteche Sacrum) 0.5-1% - Arnica Montana Flower Extract 0.5-1% - Hydrolyzed Hyaluronic Acid oligo 0.05-0.1% - Nipagin (Para hydroxy methyl benzoate) or other preservative 0.1-0.15% - Purified water qs.ad 100 3. Biologically active product in the form of a restructuring, scarring cream, characterized by the fact that it consists in mass percentages of - Polyclonal or monoclonal antibodies depending on the bacteriological profile of the patient 10-40% - Squalane 5-10% - Caprylic Capric Triglycerides 3-5% - Emulium Delta GATEFOSSE (Cetearyl Alcohol, Glyceryl Stearate) 3-5% - Sodium PCA 2-4% - Anesthesia 1-2% - Glyceryl stearate 1-2% - PEG-8 Beeswax 1-2% - Betaine from beets 1-2% - Essential amino acids 1-2% - lntegrin-60 oligopeptides from rice 1-2% -Euxyl PE 9010 0.5-0.8% - Hippophae Rhamnoides Oii 0.5-1% - Cannabidiol 0.5-1% - Amica Montana flower extract 0.5-1% - Calendula Officinalis Extract 0.5-1% - Q-enzyme Q10 0.2-0.3% - Caprylyl glycol 0.2-0.3% - Xanthan gum 0.2-0.3% - Allantoin 0.1-0.2% - Hydrolyzed hyaluronic acid 0.1-0.2% - Disodium EDTA 0.1-0.2% - Purified water qs ad qs.ad. 100 14° 4. Biologically active product in the form of ANTIACNEICTONER, characterized by the fact that it is constituted in mass percentages of - IgY antibodies against staphylococci and against Propionae bacterium Acne 10-30% - Ag-P-Water 5-10% - Azeloyl Glycine (Potassium azeloyl diglycinate) 3-5% - Butylene glycol 3-5% - Honey (White) Extract 3-5% - Glycerin 2-3% - Salixin (Salix Purpurea extract) 1-2% - Mimosa Tenuiflora bark extract 1-2% - Epilobium Angustifolium Bark extract 1-2% - Retinaturel 05 0.5-1% - Hydrolyzed Milk Protein 0.5-1% - Euxyl PE 9010 0.5-0.8% - Caprylyl Glycol 0.2-0.3% - Allantoin 0.1-0.2% - Purified water qs.ad 100 5. Biologically active product in the form of ANTI-ACNE OIL FREE GEL, characterized by the fact that it is constituted in mass percentages of - IgY antibodies against staphylococcus and against Propionum bacterium 10-50% - Honey (White) extract 3-5% - Genencare OSMS BA 1-2% - Matmarine (Pseudoalteromonas Ferment Extract) 3-5% - Iris Florentina extract, zinc sulfate, retinyl palmitate) 2-4% - Salixin (Salix Purpurea) Extract 1-2% - Calendula Oficinalis flower extract 1-2% - RETINATURELO5 0.5-1% - Ammonium Acryloyl Dimetyl Taurate/VP Copolymer 0.3-0.5% -Euxyl PE 9010 0.6-0.8% - Simulgel EG (Sodium Acrylate/Sodium Acryloyldimethyl Taurate Copolymer/lsoxhexadecane/Polysorbate 80 1-3% - Allantoin 0.1-0.2% - Caprylyl Glycol 0.2-0.3% - Purified water q.s ad 100 6. Biologically active product in the form of an anti-acne cream, characterized by the fact that it consists in mass percentages of - IgY antibodies against staphylococcus and against PropionaebacteriumAcne 10-20% - Sour azalea 5-10% - Butylene glycol 10-15% - Emulsun (Hydrogenated Sunflower Seed Oii Polyglyceryl-3Esters (and) Hydrogenated Sunflower Seed Oii Glyceryl Esters and Cetearyl Alcohol and Sodium Stearoyl Lactylate 3-4% - Hemisqualane 3-4% - Glycerin 2-3% Saboflow VL (Sodium Polyacrylate, Hydrogenated Polydecene trideceth-6) 2-3% - Epilobium Angustifolium Bark Extract (Willowherb) 1-2% - Mimosa Tenuiflora Bark Extract 1-2% - Sepimax Zen (Polyacrylate Crosspolymer-6) 1-2% - Orgasol (Nylon 12) 1-2% - Normaseb ph (Hydrolyzed milk protein) 0.5-1% - Sebopessine (Polyisoprene, Glycine Soya Sterols) 0.5-1% - Aloe Barbadensis Leaf Extract 0.5-1% - Calendula Officinalis Flower extract 0.5-1% - Cannabidiol 0.5-1% - Euxyl PE 9010 0.5-0.8% - Alpha Bisabolol 0.2-0.3% - Caprylyl Glycol 0.2-0.3% - Allantoin 0.1-0.2% - Glycyrrhetinic Acid 0.1-0.2% - Manuka Oii (Leptospermum Scoparium Branch Leaf Oii 0.1-0.2% - Mentha Arvensis Oii 0.05-0.1% - Purified water qs ad 100 7. Biologically active product in the form of an anti-psoriasis solution, characterized by the fact that it is constituted in mass percentages of -IgY polyclonal antibodies 20-40% -Nikosome PV- 3-5% -AG-P 5-10% -Nicotnamide 3-4% -Sodium Ascorbyl Phosphate 0.5-1% -Hydrolyzed Hyaluronic Acid 0.05-0.1% - Nipagin 0.1%-0.2% -Salixin (Salix Purpurea) 1-2% -Purified water qs. ad 100 8. Biologically active product in the form of an anti-psoriasis gel, characterized by the fact that it is constituted in mass percentages of - Antibacterial and antiviral antibodies 10-30% - Sodium PCA 3-5% -Honey (White) Extract 3-5% - Genencare OSMS BA betaine from beet 1-2% - Simulgel EG 1-3% - Salixin (Salix Purpurea) 1-2% - White Betula Leaf Extract 1-2% - SacranBG (Aphanoteche Sacrum) 1-2% - Aloe Vera Gel 1-2% - Retinaturel 05 0.5-1% - Cannabidiol CBD 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% - Chelidonium Majus Extract 0.5-1% - Ammonium Acryloyl Dimethyl Taurate (Flocare) 0.3-0.5% - Caprylyl Glycol 0.2-0.3% RO 135640 AO - Juniperus Oxycedrus Wood Extract 0.1-0.2% - Melaleuca Alternifolia Oii Leaf (Tea Tree) 0.05-0.1% - Hydrolyzed Hyaluronic Acid oligo 0.05-0.1% - Purified water q.s ad.100 9. Biologically active product in the form of an anti-psoriasis restructuring cream, characterized by the fact that it is constituted in mass percentages of - Antibacterial and antiviral antibodies 5-30% -Glycerin 2-3% - Xanthan Gum 0.2-0.35% - Emulactive W (Cetearyl Alcohol, Glyceryl Stearate (and) Potassium Palmitoyl Hydrolized Wheat Protein 8-10% - Plantasens LD 10-20% -Sweet Almond Oii 5-10% -Rice Sativa (Rice) Sheep brain 5-10% -Abyssinian Oii Brassica Nigra Oii 3-5% - Squalane 3-5% -Cannabidiol 2-3% - Shea Butter (Butyrospermum Parkii) 2-5% -Nicotinamide 2-3% - Salixin (Purple Sage) Extract 1-2% - White Birch Leaf Extract 0.5-1% -Retinaturel 05 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% -Coenzyme Q10 0.05-0.1% -Tocopherol 0.2-0.3% - Caprylyl Glycol 0.2-0.3% -Hydrolyzed Hyaluronic Acid 0.05-0.1% -Melaleuca Alternifolia Sheep Leaf 0.05-0.1% - Purified water qs ad 100 10. Biologically active product in the form of a disinfectant, antibacterial solution for burns, characterized by the fact that it is constituted in mass percentages of -IgY+ polyclonal antibodies Ovomucin, Ovotransferrin, Lysozyme 20-30% -AG-P -WATER 5-10% - Honey (White) Extract 3-5% -Hydrolyzed collagen 0.5-1% -Nicotinamide 2-3% -Sodium Ascorbyl Phosphate 0.5-1% -Hydrolyzed hyaluronic acid 0.05-0.1% -Nipagin (Para Hydroxy Methyl Benzoate) 0.1-0.2% - Purified water qs.ad 100 11. Biologically active product in the form of an antibacterial, cicatrizing, restructuring gel, for burns, characterized by the fact that it is constituted in mass percentages of Polyclonal antibodies Igy- Ovomucin, Ovotransferrin, Lysozyme 10-30% - AG-P Water 5-10% - Honey (White) Extract 3-5% - Nikkosome 3-5% - Sacrum (Aphanoteche Sacrum) 1-2% - Hydrolyzed collagen 0.5-1% -Integrin 60 (Rice proteins-oligopeptides) 1-2% - Simulgel EG 1-3% -Aloe vera gel 1-2% -Cannabidiol 0.5-1% -Flocating gelling agent 0.3-0.5% - Allantoin 0.1-0.2% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.5-0.8% - Caprylyl Glycol 0.2-0.3% - Purified water qs ad 100 12. Biologically active product in the form of a moisturizing, cicatrizing, reparative cream for burns, characterized by the fact that it consists in mass percentages of -IgY+ polyclonal antibodies Ovomucin, Ovotransferrin, Lysozyme 10-30% -Glycerin 1-3% - Xanthan Gum 0.2-0.35% -Emulactive W 8-10% - Plantasens LD 10-20% -Sweet Almond 5-10% -Rice Sativa (Rice) Brain Oii 5-10% -Abyssinian Sheep Brassica Nigra 3-5% - Squalane 3-5% - Anesthesia 2-3% - Cannabidiol 1-2% - Butyrospermum Parkii 2-5% - Nicotinamide 2-3% - Integrin 60 (proteins from rice hydrolyzed oligopeptides 1-2% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% - Natural tocopherol 0.2-0.3% - Alpha Bisabolol 0.2-0.3% - Coenzyme Q10 0.1-0.2% - Allantoin 0.1-0.2% - Hydrolyzed Hyaluronic Acid Oligo 0.05-0.1% - Melaleuca Alternifolia (Tea Tree Oii) 0.05-0.1% - Purified water qs.ad 100 13. Biologically active product in the form of moisturizing, antibacterial Gel, for women's intimate hygiene, characterized by the fact that it is constituted in mass percentages of - Area-specific IgY antibodies mentioned above 20-50% -AG-P-Water silver water 3-5% - Honey (White) Extract 3-5% - Sacran (Aphanoteche Sacrum) 0.5-1% -Essential amino acids 1-2% -Genencare OSMS BA betaine from beets 1-2% -Glycerin 2-3% RO 135640 AO - Malva Sylvestris or Althea Officinalis Extract 1-2% -Aloe Vera Gel 1-2% -Octyl Palmitate 3-4% -Sepigel 305 (Polyacrylamide C13- 14lsoparaffin/Laureth 7) 2-4% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% - Caprylyl Glycol 0.2-0.3% - Allantoin 0.1-0.2% -Hydrolyzed Hyaluronic Acid 0.05-0.1% - Purified water qs.ad 100 14. Biologically active product in the form of moisturizing, antibacterial Gel, for women's intimate hygiene, characterized by the fact that it is constituted in mass percentages of -IgY antibodies specific to the genital area 10-40% - Squalane 5-10% -Caprylic Capric Triglycerides 3-5% - Emulium Delta 3-5% -Sodium PCA 2-5% -PEG 8 Beeswax 1-2% - General OSMS BA 1-2% -Essential amino acids 1-2% - Althea Officinalis or Malva Sylvestris 1-2% -Calendula Officinalis Extract 0.5-1% - Phenoxyethanol, Ethyl Hexyl Glycerin 0.6-0.8% -Cannabidiol 0.5-1% -Coenzyme Q10 0.2-0.3% - Caprylyl glycol 0.2-0.3% - Xanthan Gum 0.2-0.35% - Allantoin 0.1-0.2% - Disodium EDTA 0.1-0.2% -Hydrolyzed Hyaluronic Acid 0.05-0.1% - Purified water qs.ad 100 15. Biologically active product in the form of Intravaginal Anti-Papilloma Virus Ovules, for women, characterized by the fact that it consists in mass percentages of Immunoglobulin Y against HPV 80 mg Colloidal silicon dioxide 20 mg Recutita Chamomills extract 60 mg Vitamin E acetate 10 mg Sodium hyaluronate 5 mg Glycerides (saturated fatty acids) 1425 mg